Guerbet's Vectorio Device Receives CE Mark Approval for cTACE Procedures

 

October 4, 2017—Guerbet, a company specializing in contrast products and solutions for medical imaging, recently announced that it has obtained European CE Mark approval for Vectorio, the company's conventional transarterial chemoembolization (cTACE) mixing and injection system.

According to Guerbet, Vectorio is a set of Lipiodol-resistant medical devices including syringes, stopcocks, and sampling devices. Vectorio is designed for mixing and delivering Lipiodol ultra fluid and anticancer drugs during cTACE procedures in adults with known, intermediate-stage hepatocellular carcinoma.

Designed and manufactured in France, the Vectorio device is being launched commercially this fall in European countries, where Lipiodol ultra fluid is registered for cTACE. Vectorio provides 24 hours of Lipiodol resistance. In addition, a three-way stopcock with four connections offers the possibility of "on-table mixing," allowing interventional radiologists to remix without disconnection from the microcatheter, thus maximizing safety during the intervention, noted the company.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.